Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease.
Johannes P D SchultheissRemi MahmoudJonas M LouwersMichiel T van der KaaijBoris P van HellemondtPetra G van BoeckelNofel MahmmodBindia JharapHerma H FidderBas OldenburgPublished in: Alimentary pharmacology & therapeutics (2021)
Patients with sustained benefit to anti-TNFα after 2 years are at low risk of subsequent loss of response.